78 completed, 21 unknown, 13 recruiting, 10 terminated. 137 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 137 | Completed 78, Unknown 21, Recruiting 13, Terminated 10, Withdrawn 10, Active not recruiting 3, Not yet recruiting 2 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab. - ITP - Immune Thrombocytopenia | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 38 | 2026-06-22 | 2026-08-26 |
| Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery Nuwiq - Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2026-04-01 | 2026-05-12 |
| Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery fresh frozen plasma, prothrombin complex concentrate - Cardiac Valve Disease | Phase 4 | Recruiting | Konkuk University Medical Center | 100 | 2026-03-27 | 2026-06-17 |
| PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） PCC - Hemophilia, Inhibitors | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-03-01 | 2026-02-12 |
| A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A Hirudoid (heparinoids) ointment, 3mg/g - Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A, Crow's Feet Lines | Phase 4 | Not yet recruiting | DKSH Management (Thailand) Limited | 48 | 2026-02-01 | 2026-02-05 |
| Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP Eltrombopag, Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 150 | 2025-12-01 | 2025-09-24 |
| Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy Efanesoctocog alfa - Factor VIII Deficiency | Phase 4 | Recruiting | Sanofi | 35 | 2025-09-23 | 2026-10-15 |
| Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study Avatrombopag 20 mg Oral Tablet - ITP - Immune Thrombocytopenia | Phase 4 | Recruiting | Al-Mustansiriyah University | 25 | 2025-06-08 | 2025-08-21 |
| Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa Efanesoctocog alfa - Hemophilia A | Phase 4 | Active not recruiting | Swedish Orphan Biovitrum | 252 | 2025-05-21 | 2026-09-30 |
| Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) Advate® - Hemophilia a with Inhibitor | Phase 4 | Recruiting | Runhui WU | 110 | 2025-03-01 | 2025-03-07 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis Efanesoctocog alfa - Haemophilia A (Moderate or Severe), Hemophilia, Classic | Phase 4 | Active not recruiting | Swedish Orphan Biovitrum | 37 | 2024-12-19 | 2026-04-30 |
| A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia A | Phase 4 | Recruiting | Sanofi | 20 | 2024-03-01 | 2026-09-23 |
| Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study Nuwiq - Severe Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2023-11-28 | 2026-05-12 |
| Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery Prothrombin Complex Concentrate, Human, Fresh Frozen Plasma - Valvular Heart Surgery | Phase 4 | Terminated | SHI Jia | 476 | 2023-10-25 | 2026-06-24 |
| The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin Unfractionated heparin, Double-legged cycle ergometer exercise, Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg - Blood Coagulation Disorder | Phase 4 | Completed | Kristian Karstoft | 23 | 2023-09-22 | 2024-06-26 |
| Bridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and Pain Post-Liposuction Carboxytherapy, Placebo - Liposuction, Bruising | Phase 4 | Completed | Total Definer Research Group | 72 | 2023-09-01 | 2026-07-21 |
| An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Haemophilia Joint Health Score (HJHS) - Hemophilia A, Hemophilia B | Phase 4 | Terminated | Swedish Orphan Biovitrum | 10 | 2023-08-24 | 2025-01-16 |
| Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate - Hypofibrinogenemia, Bleeding | Phase 4 | Completed | Weill Medical College of Cornell University | 208 | 2023-04-01 | 2025-11-21 |
| TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody - Primary Immune Thrombocytopenia (ITP) | Phase 4 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 166 | 2023-02-23 | 2024-07-30 |
Showing 20 of 137. Sign in to see all of them.
Hemophilia A (67) · Purpura, Thrombocytopenic, Idiopathic (26) · Hemophilia B (15) · Hemorrhage (10) · Hemostatic Disorders (8) · Ecchymosis (5) · Thrombocytopenia (5) · Afibrinogenemia (4) · Contusions (4) · von Willebrand Diseases (4) · Hematologic Diseases (3) · Purpura (3) · Thrombocythemia, Essential (3) · Wounds and Injuries (3)
Hemic and Lymphatic Diseases (137) · Hematologic Diseases (134) · Hemorrhagic Disorders (118) · Blood Coagulation Disorders, Inherited (86) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (86) · Genetic Diseases, Inborn (86) · Coagulation Protein Disorders (81) · Pathologic Processes (48) · Pathological Conditions, Signs and Symptoms (48) · Hemorrhage (38) · Signs and Symptoms (37) · Skin Manifestations (37) · Blood Platelet Disorders (34) · Immune System Diseases (33)
Factor VIII (24) · F8 protein, human (10) · eltrombopag (9) · Dexamethasone (7) · emicizumab (7) · Factor IX (6) · Fibrinogen (5) · BAY 14-2222 (4) · recombinant factor VIII SQ (4) · Clinical Laboratory Techniques (3) · Prednisone (3) · Rituximab (3) · Tranexamic Acid (3) · factor VIII-Fc fusion protein (3) · romiplostim (3)
Baxalta now part of Shire (9) · Bayer (8) · Pfizer (8) · Shandong University (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · Wyeth is now a wholly owned subsidiary of Pfizer (5) · Swedish Orphan Biovitrum (4) · Assiut University (3) · CSL Behring (3) · Chulalongkorn University (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Bio Products Laboratory (2) · Grifols Biologicals, LLC (2) · Novartis Pharmaceuticals (2) · Octapharma (2)
United States (37) · China (26) · Italy (19) · Spain (16) · France (15) · United Kingdom (15) · Germany (14) · India (10) · Poland (9) · Brazil (8) · Sweden (8) · Canada (7) · Hungary (7) · Netherlands (7) · Romania (7)
Ming Hou, MD, PhD (2) · Alfredo E Hoyos, MD (1) · Amy D Shapiro, MD (1) · Andrew C Frisina, MS (1) · Anne S von Krogh, MD (1) · Bashir HajiBeigi, M.D. (1) · Bernard Boneu, MD (1)
PMID 19005182, PMID 11057854, PMID 14719181, PMID 15500369, PMID 15661401, PMID 1640190, PMID 17636190, PMID 18226126, PMID 19446149, PMID 19995408, PMID 20546023, PMID 20739054, PMID 21626222, PMID 21674758, PMID 21710166, PMID 22054810, PMID 22212248, PMID 22338149, PMID 22409309, PMID 22530687, PMID 22733686, PMID 2279341, PMID 2329037, PMID 23293082, PMID 23389750, PMID 23556122, PMID 23731246, PMID 23815950, PMID 24254965, PMID 24628543, PMID 24951020, PMID 25059285, PMID 25296772, PMID 25543701, PMID 25854144, PMID 25982134, PMID 26231455, PMID 26480931, PMID 26674820, PMID 26688484, PMID 27040278, PMID 27223147, PMID 27734464, PMID 28691557, PMID 28768627, PMID 29042367, PMID 29731369, PMID 30157389, PMID 30368038, PMID 30430726
2008 (3), 2009 (3), 2005 (2), 2014 (2), 2017 (2), 2023 (2), 2004 (1), 2015 (1), 2016 (1), 2018 (1)